Skip to main content
BMJ Open Access logoLink to BMJ Open Access
. 2020 Aug 14;79(9):e119. doi: 10.1136/annrheumdis-2019-216713corr1

Correction: Metformin limits osteoarthritis development and progression through activation of AMPK signalling

PMCID: PMC7854926  PMID: 32816782

Li J, Zhang B, Liu W, et al. Metformin limits osteoarthritis development and progression through activation of AMPK signalling. Ann of Rheum Dis 2020;79:635–45. doi:10.1136/annrheumdis-2019-216713.

The following funding information was missed from the final version:

This work was supported by the National Institutes of Health (NIH) Grant R01AR070222 to DC. This work was also partially supported by grants from the National Nature Science Foundation of China (NSFC) (81620108018, 81930070), and Tianjin key research and development plan, key projects for science and technology support (19YFZCSY00660) to SF. This work was also partially supported by NSFC grants (81874011, 81 572 104 and 81301531) to TW. This work was also supported by the NSFC grant (81672227) and the Frontier Science of CAS grant (QYZDB-SSW-JSC030) to HP.


Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES